https://www.selleckchem.com/pr....oducts/crenolanib-cp
In people with mild asthma poor adherence to regular therapy is common and increases the risk of exacerbations, morbidity and mortality. The use of fixed-dose combination inhalers containing an inhaled corticosteroid (ICS) and a fast-acting β -agonist (FABA) is established in moderate asthma, but they may also have potential utility in mild asthma. To evaluate the efficacy and safety of single combined FABA/ICS inhaler only used as needed in people with mild asthma. Cochrane meta-analysis of available trial data. Children a